Study shows a serious risk of side effects when having latent tuberculosis therapy over age 65
Key points
- A new study found that there is a serious increased risk of side effects requiring hospitalization in people over the age of 65 who are going through latent tuberculosis infection therapy, according to a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only).
- Latent tuberculosis therapy has been shown to reduce the development of active tuberculosis (TB) disease and is used as a way to control tuberculosis in Canada and the United States.
- "The primary objective for this study was to derive population-based estimates for rates of severe adverse events associated with therapy for latent tuberculosis in different age groups," writes Dr.
- The results of this study showed serious adverse reactions.
A new study found that there is a serious increased risk of side effects requiring hospitalization in people over the age of 65 who are going through latent tuberculosis infection therapy, according to a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only).
Latent tuberculosis therapy has been shown to reduce the development of active tuberculosis (TB) disease and is used as a way to control tuberculosis in Canada and the United States. Deciding to treat a person with latent tuberculosis therapy depends on the risk of developing the active disease and having adverse reactions.
"The primary objective for this study was to derive population-based estimates for rates of severe adverse events associated with therapy for latent tuberculosis in different age groups," writes Dr. Dick Menzies, Montréal Chest Institute, and coauthors.
The results of this study showed serious adverse reactions. These reactions, related to latent TB therapy, were based on five predefined conditions: hepatic (noninfectious/toxic hepatitis,) gastrointestinal (dyspepsia, vomiting), hematologic (thrombocytopenia), allergy (dermatitis) or poisoning.
"Our study provides estimates of the risk of latent TB therapy related adverse events requiring hospitalization," conclude the authors. "These risk estimates are age stratified, are based on virtually all patients treated among a large population during six-years, and account for comorbidities and the occurrence of similar health events in the general population."
###
Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
NewsSpanish nurse becomes first to contract Ebola outside West Africa
A Spanish nurse has become the first person to contract Ebola outside of Africa, casting doubt over measures taken in Spain to control the potential spread of the deadly disease. The nurse had helped to treat two…
7 October 2014
NewsStudy shows complexities of reducing HIV rates in Russia
Results of a new study conducted in St. Petersburg, Russia, show that decreasing HIV transmission among Russian HIV-infected drinkers will require creative and innovative approaches. While new HIV infections globally…
5 September 2014
NewsGrowth hormone analog may reduce risk of fatty liver disease in HIV-infected patients
In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study…
